Abstracts tagged "Vasculitis"

Abstract Number: 1780 • 2014 ACR/ARHP Annual Meeting
Outcomes of Triple Therapy (Plasma Exchange, Cyclophosphamide and Systemic Corticosteroid) for Anti-Neutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitis
Joanna Ueng¹, Katerina Pavenski² and Laurence Rubin³, ¹Rheumatology/Medicine, University of Toronto, Toronto, ON, Canada, ²Transfusion Medicine, St. Michael's Hospital, Toronto, ON, Canada, ³Rheumatology, St. Michael Hospital, Toronto, ON, Canada
Background/Purpose Microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and Churg-Strauss Syndrome (CSS) are syndromes known as ANCA-associated vasculitis (AAV). In addition to immunosuppressive therapy, plasma…
Abstract Number: 2851 • 2014 ACR/ARHP Annual Meeting
The Relationship of ARMS2 Genotype with Idiopathic Inflammatory Vasculitis
Christopher Mecoli¹, Fan Wang², Christopher Pappas³, Peter C. Grayson⁴, David Cuthbertson⁵, Simon Carette⁶, Christian Pagnoux⁶, Gary S. Hoffman⁷, Nader A. Khalidi⁸, Curry L. Koening⁹, Carol A. Langford¹⁰, Carol McAlear¹¹, Paul A. Monach¹², Larry W. Moreland¹³, Philip Seo¹⁴, Ulrich Specks¹⁵, Steven R. Ytterberg¹⁶, Rui Feng¹⁷, Gregory Hageman³ and Peter A. Merkel¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, OK, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ⁵Department of Biostatistics, University of South Florida, Tampa, FL, ⁶Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ⁹Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹²Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹³Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁵Frederichs Dr NW, Mayo Clinic, Rochester, MN, ¹⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁷Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Patients with age-related macular degeneration (AMD), a leading cause of irreversible blindness, have a 10-fold increased prevalence of abdominal aortic aneurysms. Single nucleotide polymorphisms…
Abstract Number: 2764 • 2014 ACR/ARHP Annual Meeting
S100B Astrocyte Protein May Serve As a Prognostic Factor in Reversible Cerebral Vasoconstrictive Syndromes
Juan J. Maya¹, Vikram Puvenna^2,3,4, Chanda Brennan^2,3,5, Seby John⁶, Ken Uchino⁷, Leonard H. Calabrese⁸, Damir Janigro^2,4,9,10 and Rula Hajj-Ali¹¹, ¹Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, ²Cerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ³Neurosurgery, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ⁴Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ⁵Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ⁶9500 Euclid Avenue S10-C, Cleveland Clinic Foundation, Cleveland, OH, ⁷Neurology, Cleveland Clinic Foundation, Cleveland, OH, ⁸Cleveland Clinic Foundation, Cleveland, OH, ⁹Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ¹⁰Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ¹¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Reversible Cerebral Vasoconstriction Syndromes (RCVS) are a group of disorders characterized by acute onset of recurrent thunderclap headaches with or without neurologic deficits. Radiologically,…
Abstract Number: 1788 • 2014 ACR/ARHP Annual Meeting
Association of HLA-B*41 with Henoch-Schönlein Purpura in Spanish Individuals Irrespective of the HLA-DRB1 Status
Fernanda Genre¹, Raquel López-Mejías¹, Belén Sevilla Pérez², Santos Castañeda³, Norberto Ortego-Centeno², Javier Llorca⁴, Begoña Ubilla¹, Trinitario Pina Murcia¹, Vanesa Calvo-Río⁵, Ana Márquez⁶, Luis Sala-Icardo⁷, Jose A. Miranda-Filloy⁸, Marta Conde-Jaldón⁹, Lourdes Ortiz-Fernández⁹, Juan María Blanco-Madrigal¹⁰, Eva Galindez-Agirregoikoa¹⁰, Francisca González Escribano⁹, Javier Martin¹¹, Ricardo Blanco¹² and MA González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Medicine Department, Hospital Universitario San Cecilio, Granada, Spain, ³Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁵Av. Cardenal Herrera Oria s/n - Lab. 201, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ⁶Instituto de Parasitologia y Biomedicina López-Neyra (IPBLN-CSIC) and Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁸Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, ⁹Immunology department, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁰Rheumatology Department. Basurto University Hospital, Bilbao, Spain, ¹¹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ¹²Hospital Marques de Valdecilla, Santander, Spain
Background/Purpose: Henoch-Schönlein purpura (HSP), the most common type of primary small-sized blood vessel leukocytoclastic vasculitis, is characterized by infiltration of the small blood vessels with…
Abstract Number: 2787 • 2013 ACR/ARHP Annual Meeting
The Effect Of Smoking On The Clinical Expression Of ANCA-Associated Vasculitis
Neil Basu¹, Aladdin Mohammad², Richard A. Watts³, Paul Gatenby⁴, Luis F. Flores-Suarez⁵ and Alfred Mahr⁶, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Department of Rheumatology, Skåne University Hospital, Lund, Sweden, ³Rheumatology Department Ipswich Hospital and University of East Anglia, Ipswich, United Kingdom, ⁴ANU Medical School, The Canberra Hospital, Canberra, Australia, ⁵Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ⁶Department of Internal Medicine, Hospital Saint-Louis, Paris, France
Background/Purpose: It is well recognized that smoking has immuno-modulatory effects in several chronic inflammatory disorders. For ANCA-associated vasculitis (AAV), which includes granulomatosis with polyangiitis (GPA)…
Abstract Number: 2633 • 2013 ACR/ARHP Annual Meeting
Clinical Spectrum Of Cutaneous Vasculitis
Javier Loricera¹, Vanesa Calvo-Río¹, Francisco Ortiz-Sanjuan², Héctor Fernández-Llaca³, Marcos A. González-López⁴, Lino Álvarez⁵, M. Carmen González-Vela⁶, Domingo González-Lamuño⁷, Cristina Mata², Javier Rueda-Gotor⁸, Víctor M. Martínez-Taboada⁹, Miguel Angel González-Gay² and Ricardo Blanco¹⁰, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ³Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ⁴Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Pediatrics, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁶Pathology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ⁷Pediatrics, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander, Santander, Spain, ⁸Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, ¹⁰Hospital Marques de Valdecilla, Santander, Spain
Background/Purpose: Cutaneous vasculitis (CV) encompasses a large and heterogeneous set of syndromes characterized by inflammation of the skin vessels. The most common clinical manifestation is…
Abstract Number: 1657 • 2013 ACR/ARHP Annual Meeting
Enothelin-1 Plays a Role In The Pathogenesis Of Reversible Cerebral Vasoconstriction Syndrome
Tariq Hammad¹, Leonard H. Calabrese², Ken Uchino³, Seby John³, Mark Stillman⁴, Stewart Tepper⁴, Colin O'Rourke⁵, Allison Janocha¹, Serpil Erzurum¹ and Rula Hajj-Ali⁴, ¹Cleveland Clinic, Cleveland, OH, ²Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ³Neurology, Cleveland Clinic Foundation, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH, ⁵Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
Background/Purpose: Cerebral vasoconstriction is thought to be the underlying pathogenetic mechanism of Reversible Cerebral Vasoconstriction Syndromes (RCVS). However, mediators of the syndrome at molecular levels…
Abstract Number: 1660 • 2013 ACR/ARHP Annual Meeting
Primary Central Nervous System Vasculitis: Treatment and Course
Carlo Salvarani¹, Robert D. Brown Jr.², Teresa J. H. Christianson², John Huston III², Kenneth Calamia³, Caterina Giannini² and Gene G. Hunder⁴, ¹Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Jacksonville, FL, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: To determine the response to therapy and long-term outcome of PCNSV we reviewed all cases of PCNSV seen over a 29-year period. Methods:…
Abstract Number: 854 • 2013 ACR/ARHP Annual Meeting
Aortic Wall Thickness In Patients Without Aortitis: a Computed Tomography-Based Study Of 100 Patients
Afif Nakhleh¹, Irina Rukhkyan², Vladimir Wolfson³, Itzhak A. Rosner⁴, Majed Odeh⁴ and Gleb Slobodin⁵, ¹Internal Medicine, Bnai Zion Medical Center, Haifa, Israel, ²Rehabilition, Bnai Zion Medical Center, Haifa, Israel, ³Radiology, Bnai Zion Medical Center, Haifa, Israel, ⁴Bnai Zion Medical Center, Haifa, Israel, ⁵Rheumatology, Bnai Zion Medical Center, Haifa, Israel
Background/Purpose: Thickening of the aortic wall, probably the earliest CT sign of aortitis, is frequently missed as there are no accepted criteria for normal aortic…
Abstract Number: 2566 • 2012 ACR/ARHP Annual Meeting
Aβ-Related Angiitis: Comparison with Patients with Amyloid Cerebral Angiopathy without Inflammation
Carlo Salvarani¹, Caterina Giannini², Robert D. Brown Jr.², Teresa J. H. Christianson² and Gene G. Hunder³, ¹Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ²Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Coexistence of sporadic cerebral amyloid angiopathy (CAA) and primary central nervous system vasculitis (PCNSV) has been reported, particularly in patients with granulomatous vasculitis. This…
Abstract Number: 2388 • 2012 ACR/ARHP Annual Meeting
Urticarial Vasculitis: Clinical Study
Javier Loricera¹, Vanesa Calvo-Rio², Francisco Ortiz Sanjuan², Marcos Antonio Gonzalez-Lopez³, Hector Fernandez-Llaca³, Javier Rueda-Gotor², Carmen Gonzalez-Vela⁴, Cristina Mata-Arnaiz⁵, Jose Luis Peña-Sagredo², Miguel A. Gonzalez-Gay² and Ricardo Blanco², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ³Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁴Pathology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Rheumatology, Hospital Laredo, Santander, Spain
Background/Purpose: Urticarial vasculitis is an infrecuent subset of vasculitis described by McDuffy et al, in 1973, characterized clinically by urticarial skin lesions of more than…
Abstract Number: 2391 • 2012 ACR/ARHP Annual Meeting
New Disease Manifestations After Diagnosis in Six Types of Vasculitis
Peter C. Grayson¹, David Cuthbertson², Simon Carette³, Gary S. Hoffman⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Kathleen Maksimowicz-McKinnon⁸, Paul A. Monach⁹, Philip Seo¹⁰, Ulrich Specks¹¹, Steven R. Ytterberg¹² and Peter A. Merkel¹³, ¹Section of Rheumatology & the Clinical Epidemiology Unit, Boston University School of Medicine, Vasculitis Center, Boston, MA, ²Department of Biostatistics, University of South Florida, Tampa, FL, ³Div of Rheum/E1-422, UHN/MSH, Toronto, ON, Canada, ⁴Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁵Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, ⁷Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology, Boston University, Boston, MA, ¹⁰Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology Division, Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: The proportion of patients who experience new manifestations of vasculitis after diagnosis is unknown. Our objectives were to quantify the occurrence of new…
Abstract Number: 2365 • 2012 ACR/ARHP Annual Meeting
Asymptomatic Myocardial Ischemic Disease in Takayasu’s Arteritis
Chloe Comarmond¹, Odile Dessault², jean-Yves Devaux², Nathalie Costedoat-Chalumeau³, Mathieu Resche Rigon⁴, Richard Isnard⁵, Fabien Koskas⁶, Patrice Cacoub Sr.⁷ and David Saadoun⁸, ¹Internal Medicine, Hôpital Pitié Salpétrière, Paris, France, ²Department of Nuclear Medicine, Groupe Hospitalier Saint-Antoine, Paris, France, ³Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁴Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ⁵Cardiology, CHU Pitié-Salpêtrière, 47-83 Boulevard de l'hôpital, 75651 Paris Cedex 13, Paris, France, Paris, France, ⁶Department of Internal Medicine and 2Laboratory I3 « Immunology, Immunopathology, Immunotherapy », UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ⁷Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, ⁸DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France
Background/Purpose: Cardiac involvement in Takayasu's arteritis (TA) is a leading cause of death. Previous studies reported a high incidence of myocardial involvement using exercise thallium-201…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].